Socías ME, Dong H, Wood E, Brar R, Richardson L, Hayashi K, Kerr T, Milloy MJ Trajectories of retention in opioid agonist therapy in a Canadian setting Int J Drug Policy, 2020. PubMed
Varghese N, Knight R, Gallagher L, Ti L Treatment of hepatitis C virus infection in marginalized populations Am J Nurs, 2020. PubMed
Lake S, Socías ME, Milloy MJ Evidence shows that cannabis has fewer relative harms than opioids CMAJ, 2020. PubMed
Wilson T, Brar R, Sutherland C, Nolan S Use of a primary care and pharmacy-based model for the delivery of injectable opioid agonist treatment for severe opioid use disorder: a case report CMAJ, 2020. PubMed
Lake S, Kerr T, Buxton J, Walsh Z, Marshall BDL, Wood E, Milloy MJ Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians J Psychopharmacol, 2020. PubMed
Danilewitz M, McLean M High-dose buprenorphine for treatment of high potency opioid use disorder Drug Alcohol Rev, 2020. PubMed
Collins AB, Boyd J, Hayashi K, Cooper HLF, Goldenberg S, McNeil R Women's utilization of housing-based overdose prevention sites in Vancouver, Canada: an ethnographic study Int J Drug Policy, 2020. PubMed
McAdam M, Brar R, Young S Initiation of injectable opioid agonist treatment in hospital: a case report Drug Alcohol Rev, 2020. PubMed
Randhawa P, Brar R, Nolan S Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market CMAJ, 2020. PubMed
van Draanen J Unique roles of childhood poverty and adversity in the development of lifetime co-occurring disorder SSM Popul Health, 2020. PubMed